XML 40 R47.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidating Financial Information (Tables)
 12 Months Ended
Mar. 30, 2012
Condensed Financial Information of Parent Company Only Disclosure [Abstract]  
Schedule Of Condensed Consolidated Statement Of Financial Position [Table Text Block]
   Parent Guarantor Subsidiaries (a) Non-Guarantor Subsidiaries Eliminations Consolidated
ASSETS              
Current Assets:              
 Cash and cash equivalents$ 117,448 $ 13,530 $ 32,174 $ - $ 163,152
 Accounts receivable, net   139,502   116,574   1,624   -   257,700
 Inventories  117,684   95,611   291   -   213,586
 Deferred tax assets, net   12,552   4,410   -   -   16,962
 Intercompany receivable  257,349   -   -   (257,349)   -
 Prepaid expenses and other current assets  22,879   11,295   118   -   34,292
  Total current assets   667,414   241,420   34,207   (257,349)   685,692
Property and equipment, net   40,074   60,676   286   -   101,036
Other Assets:              
 Goodwill   43,270   158,482   -   -   201,752
 Intangibles, net  18,518   36,082   -   -   54,600
 Investment in subsidiaries  390,811   24,084   -   (414,895)   -
 Other assets  95,950   18,867   717   (2,644)   112,890
  Total assets$ 1,256,037 $ 539,611 $ 35,210 $ (674,888) $ 1,155,970
                 
LIABILITIES AND EQUITY              
Current Liabilities:              
 Accounts payable $ 125,363 $ 20,462 $ 708 $ - $ 146,533
 Accrued expenses   20,833   20,449   471   -   41,753
 Intercompany payable  -   269,121   7,163   (276,284)   -
 Other current liabilities  (62,131)   74,200   (28)   -   12,041
  Total current liabilities   84,065   384,232   8,314   (276,284)   200,327
                 
Revolving line of credit and long-term debt, excluding current portion   454,916   -   2,579   (2,579)   454,916
Other noncurrent liabilities   85,401   24,515   -   -   109,916
  Total liabilities  624,382   408,747   10,893   (278,863)   765,159
  Total PSS World Medical, Inc. shareholders' equity  631,655   130,270   24,317   (399,114)   387,128
 Noncontrolling interest  -   594   -   3,089   3,683
  Total equity  631,655   130,864   24,317   (396,025)   390,811
  Total liabilities and equity $ 1,256,037 $ 539,611 $ 35,210 $ (674,888) $ 1,155,970

   Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated
ASSETS              
Current Assets:              
 Cash and cash equivalents$ 13,901 $ 3,568 $ 11,879 $ - $ 29,348
 Accounts receivable, net   132,425   113,347   1,457   -   247,229
 Inventories  121,350   91,501   360   -   213,211
 Deferred tax assets, net   15,772   4,761   -   -   20,533
 Intercompany receivable  156,051   -   403   (156,454)   -
 Prepaid expenses and other current assets  20,515   13,633   137   -   34,285
  Total current assets   460,014   226,810   14,236   (156,454)   544,606
Property and equipment, net   44,456   57,588   357   -   102,401
Other Assets:              
 Goodwill   37,518   129,576   -   -   167,094
 Intangibles, net  18,390   23,489   -   -   41,879
 Investment in subsidiaries  446,526   10,913   -   (457,439)   -
 Other assets  80,396   16,975   741   (2,420)   95,692
  Total assets$ 1,087,300 $ 465,351 $ 15,334 $ (616,313) $ 951,672
                 
LIABILITIES AND EQUITY              
Current Liabilities:              
 Accounts payable $ 91,936 $ 34,729 $ 1,392 $ - $ 128,057
 Accrued expenses   22,241   14,411   523   -   37,175
 Current portion of long-term debt   39   722   -   -   761
 Intercompany payable  -   166,317   -   (166,317)   -
 Other current liabilities  (39,191)   72,402   -   -   33,211
  Total current liabilities   75,025   288,581   1,915   (166,317)   199,204
                 
Revolving line of credit and long-term debt, excluding current portion   195,656   6   2,435   (2,435)   195,662
Other noncurrent liabilities   84,136   26,144   -   -   110,280
  Total liabilities  354,817   314,731   4,350   (168,752)   505,146
Equity:              
 PSS World Medical Inc. shareholders' equity:              
  Total PSS World Medical, Inc. shareholders' equity  732,483   150,189   10,984   (450,730)   442,926
 Noncontrolling interest  -   431   -   3,169   3,600
  Total equity  732,483   150,620   10,984   (447,561)   446,526
  Total liabilities and equity $ 1,087,300 $ 465,351 $ 15,334 $ (616,313) $ 951,672
Schedule Of Condensed Consolidated Statement Of Operations [Table Text Block]
   Parent Guarantor Subsidiaries (a) Non-Guarantor Subsidiaries Eliminations Consolidated
Net sales $ 1,219,631 $ 861,179 $ 73,278 $ (52,086) $ 2,102,002
Cost of goods sold   864,473   548,221   51,993   (36,888)   1,427,799
  Gross profit  355,158   312,958   21,285   (15,198)   674,203
General and administrative expenses  203,371   182,345   7,536   (262)   392,990
Selling expenses   100,732   47,125   -   -   147,857
Equity earnings of subsidiaries  (55,715)   13,171   -   42,544   -
  (Loss) income from operations   (4,660)   96,659   13,749   27,608   133,356
Other (expense) income:              
 Interest expense   (19,605)   (344)   (275)   76   (20,148)
 Interest income  9,553   (9,304)   -   (76)   173
 Other income, net   1,334   759   (9)   -   2,084
  Other expense, net  (8,718)   (8,889)   (284)   -   (17,891)
(Loss) income before provision for income taxes   (13,378)   87,770   13,465   27,608   115,465
(Benefit) provision for income taxes   (18,226)   59,159   130   -   41,063
Net income   4,848   28,611   13,335   27,608   74,402
Net income attributable to noncontrolling interest  -   162   -   (79)   83
Net income attributable to PSS World Medical, Inc.$ 4,848 $ 28,449 $ 13,335 $ 27,687 $ 74,319

   Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated
Net sales $ 1,302,655 $ 831,776 $ 15,658 $ (115,300) $ 2,034,789
Cost of goods sold   965,219   537,263   5,695   (109,159)   1,399,018
  Gross profit  337,436   294,513   9,963   (6,141)   635,771
General and administrative expenses  204,804   155,275   4,812   (142)   364,749
Selling expenses   97,371   40,095   -   -   137,466
Equity earnings of subsidiaries  38,512   3,607   -   (42,119)   -
  Income from operations   73,773   102,750   5,151   (48,118)   133,556
Other (expense) income:              
 Interest expense   (16,668)   (233)   (220)   -   (17,121)
 Interest income   9,303   (9,019)   -   -   284
 Other income, net   1,730   776   -   -   2,506
  Other expense, net  (5,635)   (8,476)   (220)   -   (14,331)
Income before provision for income taxes   68,138   94,274   4,931   (48,118)   119,225
(Benefit) provision for income taxes   (17,616)   61,991   186   -   44,561
Net income   85,754   32,283   4,745   (48,118)   74,664
Net income attributable to noncontrolling interest  -   71   -   108   179
Net income attributable to PSS World Medical, Inc.$ 85,754 $ 32,212 $ 4,745 $ (48,226) $ 74,485

   Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated
Net sales $ 1,345,645 $ 831,570 $ - $ (122,044) $ 2,055,171
Cost of goods sold   1,004,697   544,823   (6,795)   (115,249)   1,427,476
  Gross profit  340,948   286,747   6,795   (6,795)   627,695
General and administrative expenses  218,248   151,200   1,423   -   370,871
Selling expenses   97,292   38,551   -   -   135,843
Equity earnings of subsidiaries  29,984   5,372   -   (35,356)   -
  Income from operations   55,392   102,368   5,372   (42,151)   120,981
Other (expense) income:              
 Interest expense   (17,156)   (139)   -   -   (17,295)
 Interest income   9,842   (9,466)   -   -   376
 Other income, net   5,207   861   -   -   6,068
  Other expense, net  (2,107)   (8,744)   -   -   (10,851)
Income before provision for income taxes   53,285   93,624   5,372   (42,151)   110,130
(Benefit) provision for income taxes   (21,127)   61,894   -   -   40,767
Net income   74,412   31,730   5,372   (42,151)   69,363
Net income attributable to PSS World Medical, Inc.$ 74,412 $ 31,730 $ 5,372 $ (42,151) $ 69,363
Schedule Of Condensed Consolidated Statement Of Cash Flows [Table Text Block]
    Parent Guarantor Subsidiaries (a) Non-Guarantor Subsidiaries Eliminations Consolidated
Cash Flows From Operating Activities:              
   Net cash (used in) provided by operating activities$ (30,477) $ 138,616 $ 20,184 $ (39) $ 128,284
Cash Flows From Investing Activities:              
 Payments for business combinations, net of cash acquired  (8,599)   (56,532)   -   -   (65,131)
 Capital expenditures  (2,597)   (21,288)   (33)   -   (23,918)
 Other  (268)   (78)   -   183   (163)
   Net cash used in investing activities  (11,464)   (77,898)   (33)   183   (89,212)
Cash Flows From Financing Activities:              
 Proceeds from issuance of debt  250,000   -   -   -   250,000
 Proceeds from borrowings on the revolving line of credit  405,056   -   144   (144)   405,056
 Repayments on the revolving line of credit  (405,056)   -   -   -   (405,056)
 Purchase and retirement of common stock  (140,439)   -   -   -   (140,439)
 Payment of contingent consideration on business acquisition  -   (9,500)   -   -   (9,500)
 Payment for debt issuance costs  (6,467)   -   -   -   (6,467)
 Excess tax benefits from share-based compensation arrangements  2,057   -   -   -   2,057
 Proceeds from exercise of stock options  1,383   -   -   -   1,383
 Payments under capital lease obligations  (38)   (741)   -   -   (779)
 Intercompany dividend  40,515   (40,515)   -   -   -
 Other  (1,523)   -   -   -   (1,523)
   Net cash provided by (used in) financing activities  145,488   (50,756)   144   (144)   94,732
                  
 Net increase in cash and cash equivalents  103,547   9,962   20,295   -   133,804
 Cash and cash equivalents, beginning of period  13,901   3,568   11,879   -   29,348
 Cash and cash equivalents, end of period$ 117,448 $ 13,530 $ 32,174 $ - $ 163,152

    Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated
Cash Flows From Operating Activities:              
   Net cash (used in) provided by operating activities$ (852) $ 116,284 $ 3,424 $ (2,528) $ 116,328
Cash Flows From Investing Activities:              
 Payments for business combinations, net of cash acquired  (10,177)   (55,875)   -   118   (65,934)
 Capital expenditures  (2,169)   (15,784)   (489)   215   (18,227)
 Payment for investment in variable interest entity, net of cash  -   (7,431)   -   4,154   (3,277)
 Other  (527)   (24)   -   (117)   (668)
   Net cash used in investing activities  (12,873)   (79,114)   (489)   4,370   (88,106)
Cash Flows From Financing Activities:              
 Proceeds from borrowings on the revolving line of credit  106,400   -   1,429   (1,429)   106,400
 Repayments on the revolving line of credit  (106,400)   -   -   -   (106,400)
 Purchase and retirement of common stock  (54,761)   -   -   -   (54,761)
 Payment of contingent consideration on business acquisition  -   (862)   -   -   (862)
 Excess tax benefits from share-based compensation arrangements  3,187   -   -   -   3,187
 Proceeds from exercise of stock options  2,079   -   -   -   2,079
 Payments under capital lease obligations  (44)   (790)   -   -   (834)
 Intercompany dividend  41,811   (41,812)   -   1   -
 Other  (20)   -   -   (414)   (434)
   Net cash (used in) provided by financing activities  (7,748)   (43,464)   1,429   (1,842)   (51,625)
                  
 Net (decrease) increase in cash and cash equivalents  (21,473)   (6,294)   4,364   -   (23,403)
 Cash and cash equivalents, beginning of period  35,374   9,862   7,515   -   52,751
 Cash and cash equivalents, end of period$ 13,901 $ 3,568 $ 11,879 $ - $ 29,348

    Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated
Cash Flows From Operating Activities:              
   Net cash provided by operating activities$ 22,970 $ 75,076 $ 4,909 $ (554) $ 102,401
Cash Flows From Investing Activities:              
 Payments for business combinations, net of cash acquired  (1,647)   (13,155)   -   -   (14,802)
 Capital expenditures  (11,897)   (14,325)   (31)   330   (25,923)
 Proceeds from sale of available for sale securities  10,681   -   -   -   10,681
 Other  (735)   -   -   194   (541)
   Net cash used in investing activities  (3,598)   (27,480)   (31)   524   (30,585)
Cash Flows From Financing Activities:              
 Proceeds from borrowings on the revolving line of credit  5,350   -   -   -   5,350
 Repayments on the revolving line of credit  (55,350)   -   -   -   (55,350)
 Purchase and retirement of common stock  (57,176)   -   -   -   (57,176)
 Excess tax benefits from share-based compensation arrangements  2,516   -   -   -   2,516
 Proceeds from exercise of stock options  4,489   -   -   -   4,489
 Payments under capital lease obligations  (94)   (861)   -   30   (925)
 Intercompany dividends  41,515   (41,515)   -   -   -
   Net cash used in financing activities  (58,750)   (42,376)   -   30   (101,096)
                  
 Net (decrease) increase in cash and cash equivalents  (39,378)   5,220   4,878   -   (29,280)
 Cash and cash equivalents, beginning of period  74,752   4,642   2,637   -   82,031
 Cash and cash equivalents, end of period$ 35,374 $ 9,862 $ 7,515 $ - $ 52,751